Business Wire

ImpactWayv™ Launches Social Media Platform Focused on Social Good

15.6.2021 16:00:00 EEST | Business Wire | Press release

Share

ImpactWayv, Inc. today announced the public launch of its pioneering social media platform, ImpactWayv™, which is now available to download on the Apple App Store. The new platform’s focus is to connect people, businesses and philanthropy for social good.

Designed to be a healthier and more meaningful alternative to major social networking platforms, ImpactWayv was created to drive collective impact across causes and communities. The platform operates as an entirely new kind of digital ecosystem, enabling users to effect, engage in and share social impact on a global scale.

Users of ImpactWayv will be able to connect and interact with each other through each of its core components, including:

  • Public and private personal networks and content feeds to engage with and create impact.
  • The “Impact Market” – a public exchange of transparent impact profiles of businesses and nonprofits for all to compare, follow, engage with and directly support.
  • “Wayvs” (social impact causes, topics, trends and broader issue areas) – an organizing framework for purpose-driven content and information across the platform.

“ImpactWayv is democratizing social impact for all,” said Dan Rubino, Co-Founder, Chairman and Chief Executive Officer of ImpactWayv, Inc. “Finally, there is a purpose-built social media platform that gives consumers, brands, businesses and nonprofits a way to explore, create, engage and transact across all categories of daily life, with more meaning, more purpose and more goodwill.”

Engagement on the platform is driven by dozens of Wayvs™ ranging across social impact cause areas and covering various topics relating to the interplay of business, philanthropy and individual effort to drive social good. Some examples include Climate Action; Diversity, Equity and Inclusion (DE&I); Corporate Social Responsibility (CSR); Human Rights; Public Health; Environmental, Social and Governance (ESG); Voter Registration; and Renewable Energy. Wayvs facilitate and encourage user discoverability and engagement across the platform. Users tap them to find relevant impact discussions and initiatives, as well as like-minded individuals, companies and nonprofits that share their commitment to the causes they care about.

“An unprecedented interest in social action has been building globally for some time, further accelerated and focused by recent events,” said George Dolatly, Co-Founder and President of ImpactWayv, Inc. “People need a way to explore and express their values. Businesses need to use their resources and influence to make things better. And nonprofits need to leverage their missions for maximum effectiveness. ImpactWayv meets this unique moment in time by linking people and organizations around the world on a deeper level.”

To catalyze user engagement, ImpactWayv also created a groundbreaking tool to measure a user’s impact on their digital community, through the platform’s signature “Impact” metric, which tracks a user’s positive “ripple effect” across the platform, in real time.

“Our ambition at ImpactWayv is to disrupt and transform the worlds of business and philanthropy through technology,” said Benji Bernstein, Co-Founder and Chief Technology Officer of ImpactWayv, Inc. “Through our extraordinary blend of seasoned leaders and trailblazers in the worlds of corporate purpose, philanthropy and technology, we believe we have created a powerful business model that will advance universal social good.”

ImpactWayv is now available for free download on the Apple App Store and will be available on Google Play and other non-iOS devices later this year. Companies and nonprofits are also invited to contact ImpactWayv to become a member of the platform, which will enable them to claim their profile, initiate an engagement strategy on ImpactWayv and become a “Featured Organization” on the platform.

About ImpactWayv, Inc.
ImpactWayv, Inc. is a social impact media and technology company, consisting of thought leaders and doers from across the business, nonprofit and technology sectors. ImpactWayv was created to disrupt and transform the worlds of business and philanthropy through technology – to advance universal social good. For more information, please visit: www.impactwayv.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media
Jonathan Younger
214-259-3426
jonathan.younger@ketchum.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye